Advertisement

Topics

PubMed Journals Articles About "Latanoprost Xalatan Ocular Hypertension" RSS

12:48 EST 20th February 2017 | BioPortfolio

Latanoprost Xalatan Ocular Hypertension PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Latanoprost Xalatan Ocular Hypertension articles that have been published worldwide.

More Information about "Latanoprost Xalatan Ocular Hypertension" on BioPortfolio

We have published hundreds of Latanoprost Xalatan Ocular Hypertension news stories on BioPortfolio along with dozens of Latanoprost Xalatan Ocular Hypertension Clinical Trials and PubMed Articles about Latanoprost Xalatan Ocular Hypertension for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Latanoprost Xalatan Ocular Hypertension Companies in our database. You can also find out about relevant Latanoprost Xalatan Ocular Hypertension Drugs and Medications on this site too.

Showing "latanoprost Xalatan Ocular Hypertension" PubMed Articles 1–25 of 3,000+

Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study.

To evaluate the safety and efficacy of unpreserved latanoprost eye drops (UNL) in comparison with preserved latanoprost eye drops (LBAK) in patients with glaucoma or ocular hypertension stabilized with preserved latanoprost eye drops as monotherapy.


Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.

This study compared the efficacy, safety, and pharmacokinetics of a preservative-free latanoprost formulation to an established, benzalkonium chloride (BAK)-containing formulation for the treatment of open-angle glaucoma or ocular hypertension.

Hypertension and the eye.

Hypertension is the primary risk factor for cardiovascular disease and mortality that consists a major public health issue worldwide. Hypertension triggers a series of pathophysiological ocular modifications affecting significantly the retinal, choroidal, and optic nerve circulations that result in a range of ocular effects.The retina is the only place in the body where microvasculature can be directly inspected, providing valuable information on hypertension related systemic risks.The aim of this review is...


OCULAR HYPERTENSION AFTER INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANT.

To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s).

A Mouse Model of Chronic Ocular Hypertension Induced by Circumlimbal Suture.

To develop a chronic ocular hypertension mouse model by inducing intraocular pressure (IOP) elevation using a suture technique previously developed for rats.

Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa.

Success of the long-term glaucoma therapy and preservation of the visual function strongly depend on patients' compliance which may be affected by the inconvenience of treatment and its side effects. Recently, introduction of preservative-free anti-glaucoma agents has become an important step towards improved glaucoma care by eliminating the negative effects of preservatives on the eye surface. Although, newly developed eye drop formulations do not contain standard preservatives, they still can be harmful t...

Melanopsin-Containing or Non-Melanopsin-Containing Retinal Ganglion Cells Response to Acute Ocular Hypertension With or Without Brain-Derived Neurotrophic Factor Neuroprotection.

To analyze the responses of different retinal ganglion cell (RGC) types to acute ocular hypertension (AOH) and intravitreal administration of brain-derived neurotrophic factor (BDNF).

The Ocular Glymphatic System and Idiopathic Intracranial Hypertension: Author Response to "Hypodense Holes and the Ocular Glymphatic System".

Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials.

To explore factors related to the placebo effect in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).

Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.

To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.

Assessing Precision of Hodapp-Parrish-Anderson Criteria for Staging Early Glaucomatous Damage in an Ocular Hypertension Cohort: A Retrospective Study.

The aims of the study were (1) to stage early glaucomatous field defects following Hodapp-Parrish-Anderson (HPA) criteria in an ocular hypertension (OH) cohort with 7-year follow-up and (2) to recognize the limitation(s) of this staging system.

Assessing Precision of Hodapp-Parrish-Anderson Criteria for Staging Early Glaucomatous Damage in an Ocular Hypertension Cohort: A Retrospective Study.

The aims of the study were (1) to stage early glaucomatous field defects following Hodapp-Parrish-Anderson (HPA) criteria in an ocular hypertension (OH) cohort with 7-year follow-up and (2) to recognize the limitation(s) of this staging system.

Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial.

PurposeTo determine whether intraocular pressure (IOP) lowering with fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) was superior to that of vehicle+PGA in patients with open-angle glaucoma or ocular hypertension who were inadequately controlled with PGA monotherapyMethodsThis 6-week, multicenter, randomized, double-masked, parallel-group trial was conducted at 30 clinical sites in the United States between October 2013 and May 2014. Eligible patients were adults...

A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost.

Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) an...

Discriminatory Power of Superficial Vessel Density and Prelaminar Vascular Flow Index in Eyes With Glaucoma and Ocular Hypertension and Normal Eyes.

We evaluate the ability of optical coherence tomography angiography parameters, such as the peripapillary vessel density of the superficial retina and prelaminar flow index of the optic disc (PLFI), to differentiate primary open-angle glaucoma (POAG) and ocular hypertension (OH) from normal eyes.

Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study.

To assess pharmacodynamic and safety profiles of ONO-9054 following single and multiple day dosing in subjects with ocular hypertension or open-angle glaucoma.

Intraocular Pressure-Lowering Effect of Latanoprost Is Hampered by Defective Cervical Lymphatic Drainage.

To evaluate whether defects in cervical lymphatic drainage influence the intraocular pressure (IOP)-lowering effect of latanoprost in patients with primary open-angle glaucoma (POAG) who have undergone unilateral radical neck dissection (uRND).

Ocular Hypertension Requiring Suspension of Inhaled Corticosteroids.

The Relationship of Vogt-Koyanagi-Harada Syndrome to Ocular Hypertension and Glaucoma.

Vogt-Koyanagi-Harada (VKH) syndrome is a systemic inflammatory autoimmune disease with associated ophthalmic pathology. Glaucoma has been reported in patients with VKH. The purpose of this report is to examine the frequency and types of glaucoma associated with VKH.

Ocular and Cerebrospinal Fluid Penetration of Antiretroviral Agents.

The ocular penetration of systemically administered antiretroviral drugs (ARVs), which is important in the clinical setting of HIV uveitis, is unknown. This study aimed to assess the ocular penetration of different antiretroviral drugs in an animal model.

Risk Factors for Glaucoma in a Cohort of Patients with Fuchs Heterochromic Iridocyclitis.

To describe the incidence and risk factors for ocular hypertension and/or glaucoma in patients with Fuchs heterochromic iridocyclitis (FHC).

Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.

Intraocular pressure (IOP) is the most significant modifiable risk factor to prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase, emphasizing the need for improved ocular hypotensive treatment options. To try to improve on both tolerance and IOP control of currently available therapies, different receptors or mechanisms are being explored to reduce IOP more effectively and to improve tolerance.

Ocular manifestations of inflammatory bowel disease.

Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are numerous and can often involve the eye. This review highlights the ocular complications associated with IBD including the critical role the ophthalmologist can play in the diagnosis of IBD, the pathogenesis of IBD, its ocular complications, and the treatment of ocular inflammation associated with IBD.

Roles of IL-6 in Ocular Inflammation: A Review.

This review represents the current in vitro, in vivo animal and human researches on the roles of IL-6 in inflammatory ocular disorders. Data sources were literature reviewed using PubMed, Medline, and ISI Databases (since 1981 to late 2016). Search items included interleukine-6 (IL-6); chemokine; cytokine, alone or in combination with serum, aqueous, vitreous, eye, ocular, ophthalmic, and review.

The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension.

Pulmonary hypertension is a progressive disorder which often leads to right ventricular failure and death. While the existing classification system for pulmonary hypertension does not account for the impact of diabetes mellitus, evidence is emerging that suggests that diabetes is associated with pulmonary hypertension and that diabetes modifies the course of pulmonary hypertension. There is also growing radiographic, hemodynamic, biochemical, and pathologic data supporting an association between diabetes an...


Quick Search
Advertisement